Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex versus neostigmine effects on oral contraceptive levonorgestrel concentrations
ACTRN12626000073303Phase 4Not yet recruiting
- Sponsor
- ANZCA Foundation
- Start
- Feb 2026
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Sugammadex in ovulation disorder (2 arms), sponsored by ANZCA Foundation. Primary endpoint: Change in plasma levonorgestrel concentration. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
Sugammadex
03
Conditions
ovulation disorder
Beyond the preview
Go deeper on ACTRN12626000073303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000073303.